Figure 1From: Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group This graph illustrates the estimated GFR versus time (in months) prior to and after completion of the 6-month FONT Treatment Period in patients assigned to rosiglitazone.Back to article page